What is GB Sciences, Inc. (GBLX) stock price today?

GB Sciences, Inc. (GBLX) is currently trading at $0.00.

What is GBLX P/E ratio?

GB Sciences, Inc.'s P/E ratio is -0.07. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is GBLX return on equity (ROE)?

GB Sciences, Inc.'s return on equity (ROE) is 20.00%, indicating how efficiently the company generates profit from shareholders' equity. This is above the market average.

What is GB Sciences, Inc.'s market cap?

GB Sciences, Inc. has a market capitalization of $122121.

OTC · Biotechnology

GB Sciences, Inc. (GBLX) Stock

$0.00 OTC: GBLX Healthcare

Operating across North America and Europe, GB Sciences, Inc. is dedicated to the research and development of plant-based pharmaceuticals.

Valuation

Metric	Value
Price	$0.00
Market Cap	$122121
P/E Ratio	-0.07
P/B Ratio	-0.02
P/S Ratio	1.26
EPS (TTM)	$0.00
52-Week High	$0.50
52-Week Low	$0.00
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	20.00%
ROA	-438.99%
ROCE	—
Gross Margin	100.00%
Operating Margin	-68.48%
Net Margin	0.00%
Debt/Equity	-0.40
Current Ratio	0.02

Annual Financials (USD)

Metric	2019	2020	2021	2022	2023
Revenue	$3.0M	$0	$0	$0	$0
Operating Profit	$-12.0M	$-2.0M	$-2.0M	$-2.0M	$-1.0M
Net Profit	$-12.0M	$-4.0M	$-1.0M	$-4.0M	$-1.0M
EPS	$-0.04	$-0.01	$0.00	$-0.01	$0.00
Op Margin	-384.8%	—	—	—	—

Balance Sheet (USD)

Metric	2019	2020	2021	2022	2023
Total Assets	$14.0M	$11.0M	$3.0M	$0	$0
Total Liabilities	$14.0M	$12.0M	$4.0M	$5.0M	$5.0M
Cash	$0	$1.0M	$0	$0	$0
Borrowings	$9.0M	$4.0M	$1.0M	$1.0M	$2.0M

Cash Flow (USD)

Metric	2019	2020	2021	2022	2023
Operating Cash Flow	$-4.0M	$-2.0M	$-2.0M	$-2.0M	$-1.0M
Investing Cash Flow	$-1.0M	$4.0M	$1.0M	$0	$0
Financing Cash Flow	$1.0M	$0	$0	$0	$0
Net Cash Flow	$0	$1.0M	$-1.0M	$0	$0
Free Cash Flow	$-5.0M	$-2.0M	$-2.0M	$-2.0M	$-1.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.00
EV / EBITDA	-1.32
FCF Yield	-818.86%
Quick Ratio	0.02
Interest Coverage	-6.49
Return 1Y	—
Return 3Y	—
Return 5Y	—

Ownership

Insiders Held0.00%

Institutions Held0.08%

Institutions Float Held0.08%

Institutional Holder	Shares	Report Date
Kingswood Wealth Advisors, LLC	200,000	2026-06-30
Stonekeep Investments, LLC	104,930	2026-06-30

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ACUSAcusphere, Inc.	$0.00	—	0.00	$49	0.00%
BIOAFBioasis Technologies Inc.	$0.00	—	-0.12	$7941	0.00%
EHOSEhouse Global, Inc.	$0.00	—	0.00	$10127	0.00%
GSTCGlobeStar Therapeutics Corporation	$0.00	—	-0.04	$124111	0.00%
HTDSHard to Treat Diseases Inc.	$0.00	—	—	$109647	0.00%

About GB Sciences, Inc.

Operating across North America and Europe, GB Sciences, Inc. is dedicated to the research and development of plant-based pharmaceuticals. The company specializes in crafting cannabinoid-inspired medications and complex therapeutic formulations intended for the prescription drug market. Its extensive intellectual property portfolio addresses a variety of medical conditions, with programs currently in pre-clinical animal stages. These include initiatives for Parkinson's disease, neuropathic and chronic pain, COVID-related cytokine release syndrome, depression/anxiety, and cardiovascular ailments. Formed in 2001 and headquartered in Las Vegas, Nevada, the company was formerly known as Growblox Sciences, Inc. before rebranding in October 2016.

GB Sciences, Inc. (GBLX) stock trades at $0.00 with a market capitalization of $122121. The stock is valued at a price-to-earnings (P/E) ratio of -0.07, price-to-book of -0.02, price-to-sales of 1.26. Over the past 52 weeks the stock has ranged between $0.00 and $0.50, and currently trades 100.0% below its 52-week high.

On profitability, GB Sciences, Inc. generates a return on equity (ROE) of 20.00%, above the typical market average, an operating margin of -68.48%, a net profit margin of 0.00%.

Official website: www.gbsciences.com